Liffi 200 Tablet contains Cefixime 200 mg, a third-generation cephalosporin antibiotic effective against a broad spectrum of bacterial infections. Cefixime exerts its bactericidal action by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. It is commonly prescribed for the treatment of respiratory tract infections, including bronchitis and pneumonia, urinary tract infections, otitis media, pharyngitis, and gonorrhea caused by susceptible strains. Liffi 200 is indicated for both adults and pediatric patients, with dosage adjustments based on the severity of infection and renal function. The medication is well-absorbed orally, achieving adequate serum and tissue concentrations to combat systemic infections. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort, while hypersensitivity reactions are rare but possible. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Renal impairment necessitates dose modification to prevent accumulation and toxicity. Liffi 200 should be administered for the full prescribed duration to prevent resistance development and ensure complete eradication of the pathogen. It is contraindicated in individuals with known hypersensitivity to cefixime or other cephalosporins. Consultation with a healthcare professional is essential before initiating therapy.